BACKGROUND & AIMS:
IMPORTANCE:The terms "personalized oncology" and "precision oncology" have increased in usage and have generated considerable traction in terms of public attention and research funding. To our knowledge, no prior study has as thoroughly documented the use of the "precision oncology" terminology over the last decade.
OBJECTIVE:To determine how the use of the terms "personalized oncology" and "precision oncology" have changed over time.
DESIGN:A retrospective literature analysis using two databases (PubMed and Scopus) over 10 years was performed. Manuscripts using either term "personalized oncology" or "precision oncology" were collected. Manuscripts published in 2011, 2013, 2015, 2017 and through 30 June 2019 were pulled for text analysis. Common reasons for exclusion were if the search term appeared in the institution name only, the search term appeared only in keyword or publication title, or the search term was used to justify the relevance or application of research with no clear definition.
SETTING:Manuscripts published and catalogued in PubMed or Scopus.
RESULTS:In our study, we analysed 399 unique manuscripts published over the last decade. Over time, the terminology has shifted from "personalized oncology" to "precision oncology". Targeted therapy, molecular biomarker-guided tumour profiling and next generation sequencing (ie, "omics-guided tumor profiling") are the three most common definitions of the term. While these definitions are somewhat overlapping in concept, over the decade we observed an increase in the number of distinct interpretations of "precision oncology", ranging from structural biology to clinical practice.
CONCLUSIONS AND RELEVANCE:We have observed that the phrase "precision oncology" is shifting, overlapping and expanding in definition. This all-encompassing approach to defining "precision oncology" ironically renders the term imprecise. Our analysis highlights the inherent challenges in defining novel movements in medicine.
背景与目标:
重要信息:“个性化肿瘤学”和“精密肿瘤学”这两个术语的使用有所增加,并且在公众关注和研究经费方面已经产生了可观的吸引力。据我们所知,在过去的十年中,没有任何先前的研究能充分记录“精确肿瘤学”术语的使用。
目的:确定术语“个性化肿瘤学”和“精密肿瘤学”的使用随着时间的变化如何。
设计:使用两个数据库(PubMed和Scopus)进行了10年的回顾性文献分析。收集使用术语“个性化肿瘤学”或“精密肿瘤学”的手稿。分别提取2011年,2013年,2015年,2017年和2019年6月30日之前出版的手稿进行文本分析。排除的常见原因是:搜索词仅出现在机构名称中,搜索词仅出现在关键字或出版物标题中,或者使用搜索词来说明研究的相关性或应用性,而没有明确的定义。
设置:在PubMed或Scopus中出版和分类的手稿。
结果:在我们的研究中,我们分析了过去十年出版的399种独特手稿。随着时间的流逝,术语已从“个性化肿瘤学”转变为“精密肿瘤学”。靶向治疗,分子生物标志物指导的肿瘤分析和下一代测序(即“组学指导的肿瘤分析”)是该术语的三个最常见定义。尽管这些定义在概念上有些重叠,但是在过去的十年中,我们观察到从结构生物学到临床实践,对“精确肿瘤学”的不同解释的数量有所增加。
结论与相关性:我们已经观察到“精确肿瘤学”一词在定义上正在转移,重叠和扩展。具有讽刺意味的是,这种定义“精确肿瘤学”的方法使术语“不精确”成为现实。我们的分析突显了定义医学中新颖运动的内在挑战。